EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Vali Aliyev iD, Ali Kaan Güren iD, Murad Guliyev, Zeliha Birsin iD, Murat Günaltılı, Mehmet Cem Fidan, Emir Çerme, Hamza Abbasov iD, Selin Cebeci iD, Selver Işık iD, Murat Sarı iD, Onur Erdem Şahin und 3 weitere

Medicina · 05.03.2026 · 62 (3) · 488

DOI: 10.3390/medicina62030488 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medicina, online erschienen am 05.03.2026. Verfasst von Vali Aliyev und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiy…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives: Early biomarkers that can reliably predict treatment outcomes during CDK4/6 inhibitor therapy remain an unmet clinical need in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC). Metabolic changes on ^18F-FDG PET/CT may precede radiologic response and provide insight into tumor biology and early treatment resistance.

Methods

This two-center retrospective study included 203 patients with HR+/HER2− MBC who received first-line CDK4/6 inhibitors (ribociclib or palbociclib) plus endocrine therapy between 2018 and 2024. Baseline and interim ^18F-FDG PET/CT scans performed after 2–4 cycles were evaluated. Early metabolic response was defined as a ≥30% reduction in SUVmax on the most metabolically active lesion, consistent with PERCIST 1.0. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier and multivariable Cox models. ROC analysis assessed the discriminative performance of ΔSUVmax for predicting disease progression.

Results

Among 203 patients, 153 (75.4%) achieved a ≥30% SUVmax reduction. Responders had significantly longer PFS (median 44.4 vs. 4.8 months; p < 0.001) and OS (median not reached vs. 32.0 months; p < 0.001). Metabolic response remained independently associated with improved PFS (HR 0.24; 95% CI 0.15–0.37; p < 0.001) and OS (HR 0.37; 95% CI 0.20–0.67; p = 0.001) after adjustment for tumor grade, endocrine resistance, and visceral disease involvement. Non-responders demonstrated more aggressive baseline features, including higher rates of liver (34.0% vs. 15.0%) and brain metastasis (10.0% vs. 1.3%), as well as lower progesterone receptor expression (median 30% vs. 60%).

Conclusions

Early metabolic response assessed by SUV-max on interim ^18F-FDG PET/CT is independently associated with substantially improved PFS and OS in HR+/HER2− MBC receiving treatment with CDK4/6 inhibitors. Although the predictive accuracy of ΔSUVmax alone was modest, the strong survival gradient suggests meaningful prognostic value. Prospective studies with standardized imaging time points and comprehensive metabolic metrics are warranted to define the role of PET-guided treatment adaptation:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansFemaleRetrospective StudiesFluorodeoxyglucose F18PrognosisMiddle AgedErb-b2 Receptor Tyrosine KinasesAgedPyridinesAdultPiperazinesAminopyridinesPurinesProtein Kinase Inhibitors

Stichwörter der Autor:innen

CDK4/6 inhibitorsSUVmax^18F-FDG PET/CTbreast neoplasmsmetabolic responsemetastatic breast cancerprognosis

Substanzen

Fluorodeoxyglucose F18Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6PyridinespalbociclibribociclibPiperazinesAminopyridinesPurines

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
  • Division of Medical Oncology, Department of Internal Medicine, School of Medicine, Marmara University, Istanbul 34899, Türkiye.
  • Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.

ORCID-Profile: Vali Aliyev, Ali Kaan Güren, Zeliha Birsin, Hamza Abbasov, Selin Cebeci, Selver Işık, Murat Sarı, Muhammet Sait Sağer, Özkan Alan

Zitieren

APA

Aliyev, V., Güren, A. K., Guliyev, M., Birsin, Z., Günaltılı, M., Fidan, M. C., Çerme, E., Abbasov, H., Cebeci, S., Işık, S., Sarı, M., Şahin, O. E., Sağer, M. S., Alan, Ö., & Demirci, N. S. (2026). Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors. Medicina, 62(3), 488. https://doi.org/10.3390/medicina62030488

Vancouver

Aliyev V, Güren AK, Guliyev M, Birsin Z, Günaltılı M, Fidan MC, et al. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors. Medicina. 2026;62(3):488. doi:10.3390/medicina62030488

BibTeX
@article{Aliyev2026,
  author = {Aliyev, Vali and Güren, Ali Kaan and Guliyev, Murad and Birsin, Zeliha and Günaltılı, Murat and Fidan, Mehmet Cem and Çerme, Emir and Abbasov, Hamza and Cebeci, Selin and Işık, Selver and Sarı, Murat and Şahin, Onur Erdem and Sağer, Muhammet Sait and Alan, Özkan and Demirci, Nebi Serkan},
  title = {Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {3},
  pages = {488},
  doi = {10.3390/medicina62030488}
}
Kostenlos starten →